RxDoctor Payments Data

Harlicia Farley

Family Medicine · Greenville, SCNPI 1154381036

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $405 of the $630 with a category attached, or 64.3%. Novartis accounts for 78.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $497 and has fallen 75.9% since, to $120 in 2023. That places this record below the midpoint for family medicine clinicians in SC, where the typical reported total is $473.

$630in general payments, 2019–2025

Across 5 payments — averaging $125.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$497
  • Dexcom, Inc.$120
  • AbbVie$13
$1,113,237in research payments, 2019–2025

Across 342 payments — averaging $3255.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$518K
  • Exeltis, USA Inc.$235K
  • Alnylam Pharmaceuticals Inc.$169K
  • Sanofi Pasteur Inc.$122K
  • Novartis$51K
  • Lexicon Pharmaceuticals, Inc.$11K
  • plus $7K from 1 others

What the payments were for

  • Travel & lodging$22536%
  • Food & beverage$40564%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis3$497
Dexcom, Inc.1$120
AbbVie1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$630 in reported general payments places this provider in the 50th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$61,176
LinzessLinaclotide33$40,956
TrulicityDulaglutide15$30,390
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$6,435
Albuterol Sulfate HfaAlbuterol Sulfate72$3,254
Novolog FlexpenInsulin Aspart11$1,639
Omeprazole51$1,102
Gabapentin37$955
Diclofenac Sodium15$904
Fluticasone Propionate46$858
Atorvastatin Calcium96$779
Celecoxib29$773
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$721
Rosuvastatin Calcium43$563
Famotidine22$538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$13$40,95633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →